GlassScriptPhysician profile
Maria Richman
NPI 1154306264
$41,136.18
in general payments reported to CMS, 2019-2025
31 companies · $6,125 in 2025
The $6,125 reported for 2025 was more than what 99% of Low Vision Rehabilitation providers received nationally (typical 2025 total: $150).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,278 · 2020: $832 · 2021: $406 · 2022: $1,856 · 2023: $10K · 2024: $21K · 2025: $6,125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $28K · Food and Beverage: $5,753 · Travel and Lodging: $2,762.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $28,250.00 |
| Food and Beverage | $5,753.02 |
| Travel and Lodging | $2,762.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $26,874.92 | 2023-2025 | |
| Samsara Vision | $5,224.86 | 2022-2023 | |
| Johnson & Johnson Vision Care, INC. | $1,295.91 | 2019-2025 | Acuvue |
| Alcon Vision LLC | $1,006.20 | 2019-2025 | Total30, Rocklatan, Precision 1 |
| Bausch & Lomb Americas INC. | $897.03 | 2022-2025 | Infuse, Miebo, Xiidra |
| Allergan, INC. | $747.69 | 2019-2022 | |
| Biotissue Holdings INC. | $653.84 | 2023-2025 | |
| Oyster Point Pharma, INC. | $555.86 | 2022-2024 | Tyrvaya, Ryzumvi |
| Sun Pharmaceutical Industries INC. | $485.85 | 2019-2025 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $412.29 | 2019-2021 | |
| Janssen Scientific Affairs, LLC | $375.00 | 2022 | |
| Coopervision INC. | $369.81 | 2019-2025 | Misight Contact Lens, Myday Contact Lens, Paragon Crt |
| Alexion Pharmaceuticals, INC. | $352.68 | 2022-2023 | |
| Glaukos Corporation | $307.58 | 2020-2024 | Radius |
| Amgen INC. | $224.06 | 2024-2025 | Tepezza |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $179.36 | 2022-2025 | Oxervate |
| Novartis Pharmaceuticals Corporation | $151.66 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $139.38 | 2024 | Xdemvy |
| Lkc Technologies, INC. | $133.21 | 2024-2025 | |
| Apellis Pharmaceuticals, INC. | $125.00 | 2023 | Syfovre |
| Astellas Pharma US INC | $111.33 | 2024 | Izervay |
| Maculogix, INC. | $103.15 | 2019 | |
| Visioneering Technologies, INC. | $100.39 | 2019-2025 | |
| Horizon Therapeutics Plc | $75.97 | 2023 | Tepezza |
| Genzyme Corporation | $57.86 | 2022 | |
| Kala Pharmaceuticals, INC. | $49.62 | 2021-2022 | |
| Harrow Eye, LLC | $32.57 | 2024-2025 | Vevye |
| Mallinckrodt Hospital Products INC. | $32.20 | 2025 | Acthar |
| Abbvie INC. | $26.09 | 2022-2023 | |
| Alcon Research LLC | $18.98 | 2019 | |
| Thea Pharma INC. | $15.83 | 2024 | Iyuzeh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Richman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.